Allogene Therapeutics Inc. [NASDAQ: ALLO] slipped around -0.03 points on Tuesday, while shares priced at $13.43 at the close of the session, down -0.22%. The company report on October 12, 2021 that Allogene Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm.
Investors can contact the law firm at no cost to learn more about recovering their losses.
The Portnoy Law Firm advises Allogene Therapeutics, Inc. (“Therapeutics” or the “Company”) (NASDAQ: ALLO) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
Allogene Therapeutics Inc. stock is now -46.79% down from its year-to-date (YTD) trading value. ALLO Stock saw the intraday high of $13.68 and lowest of $13.01 per share. The company’s 52-week high price is 44.92, which means current price is +4.11% above from all time high which was touched on 03/16/21.
Compared to the average trading volume of 1.19M shares, ALLO reached a trading volume of 5780918 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Allogene Therapeutics Inc. [ALLO]?
Stifel have made an estimate for Allogene Therapeutics Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on October 08, 2021. While these analysts kept the previous recommendation, Goldman dropped their target price from $71 to $20. The new note on the price target was released on October 08, 2021, representing the official price target for Allogene Therapeutics Inc. stock.
The Average True Range (ATR) for Allogene Therapeutics Inc. is set at 1.67, with the Price to Sales ratio for ALLO stock in the period of the last 12 months amounting to 92.33. The Price to Book ratio for the last quarter was 1.77, with the Price to Cash per share for the same quarter was set at 2.23.
How has ALLO stock performed recently?
Allogene Therapeutics Inc. [ALLO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -44.78. With this latest performance, ALLO shares dropped by -45.78% in over the last four-week period, additionally sinking by -58.23% over the last 6 months – not to mention a drop of -67.90% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALLO stock in for the last two-week period is set at 19.31, with the RSI for the last a single of trading hit 13.59, and the three-weeks RSI is set at 24.40 for Allogene Therapeutics Inc. [ALLO]. The present Moving Average for the last 50 days of trading for this stock 23.45, while it was recorded at 17.67 for the last single week of trading, and 28.20 for the last 200 days.
Allogene Therapeutics Inc. [ALLO]: Deeper insight into the fundamentals
Return on Total Capital for ALLO is now -28.48, given the latest momentum, and Return on Invested Capital for the company is -27.64. Return on Equity for this stock declined to -29.29, with Return on Assets sitting at -25.72. When it comes to the capital structure of this company, Allogene Therapeutics Inc. [ALLO] has a Total Debt to Total Equity ratio set at 4.98. Additionally, ALLO Total Debt to Total Capital is recorded at 4.75, with Total Debt to Total Assets ending up at 4.38. Long-Term Debt to Equity for the company is recorded at 4.71, with the Long-Term Debt to Total Capital now at 4.48.
Reflecting on the efficiency of the workforce at the company, Allogene Therapeutics Inc. [ALLO] managed to generate an average of -$944,230 per employee.Allogene Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 13.10 and a Current Ratio set at 13.10.
Earnings analysis for Allogene Therapeutics Inc. [ALLO]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALLO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Allogene Therapeutics Inc. go to 1.00%.
Insider trade positions for Allogene Therapeutics Inc. [ALLO]
There are presently around $1,155 million, or 61.60% of ALLO stock, in the hands of institutional investors. The top three institutional holders of ALLO stocks are: TPG GROUP HOLDINGS (SBS) ADVISORS, INC. with ownership of 18,716,306, which is approximately 0% of the company’s market cap and around 18.60% of the total institutional ownership; BLACKROCK INC., holding 7,021,939 shares of the stock with an approximate value of $94.31 million in ALLO stocks shares; and VANGUARD GROUP INC, currently with $88.67 million in ALLO stock with ownership of nearly 10.838% of the company’s market capitalization.
Positions in Allogene Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 122 institutional holders increased their position in Allogene Therapeutics Inc. [NASDAQ:ALLO] by around 13,171,126 shares. Additionally, 58 investors decreased positions by around 16,003,780 shares, while 30 investors held positions by with 56,863,507 shares. The mentioned changes placed institutional holdings at 86,038,413 shares, according to the latest SEC report filing. ALLO stock had 42 new institutional investments in for a total of 3,460,046 shares, while 26 institutional investors sold positions of 3,423,921 shares during the same period.